Restoration® Anatomic Dual Mobility (ADM) X3® Acetabular System Study
Terminated · Not applicable · NCT01420237
Conditions: Arthroplasty, Replacement, Hip
At a glance
- Research payments reported, 2025
- $6,301
- U.S. investigators named
- 4
- Sites paid
- 4
- Planned or actual enrollment
- 367
About the trial
- Sponsor
- Stryker Orthopaedics
- Tested
- Restoration ADM X3 Device (device)
- Dates
- Started 2011-06; completion 2023-11-09
- Results posted
- Yes
The purpose of this study is to evaluate the success rate of cementless primary hip replacement with the Restoration® ADM X3® Acetabular System as compared to other primary hip systems in the literature, through absence of femoral head dislocation at 10 years postoperative.
From ClinicalTrials.gov, last updated 2025-01-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Stryker Corporation reported $6,301 in research payments for this study in 2025 (4 payments).
Products named: Accolade, X3, Restoration
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Craig J. Della Valle, M.D. Joint Replacement Surgery · Chicago, IL
- Ajay Aggarwal, M.D. Joint Replacement Surgery · Columbia, MO
- Seth S. Greenky, M.D. Joint Replacement Surgery · Liverpool, NY
- Geoffrey H. Westrich, M.D. Orthopedic Surgery · New York, NY
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- The University of Texas Health Science Center at Houston $3,478
- University of Missouri Health Care, MO $1,500
- Hospital for Special Surgery, NY $1,243
- Rush University Medical Center, IL $80
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.